A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and Boys
Latest Information Update: 06 Feb 2025
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 6 Feb 2025 to 10 Jan 2026.
- 07 Feb 2024 Planned End Date changed from 6 Feb 2024 to 6 Feb 2025.
- 05 Aug 2023 Planned End Date changed from 31 Dec 2022 to 6 Feb 2024.